List of bibliographic references indexed by Jonathan M. Brotchie
Number of relevant bibliographic references: 57.
[20-40] [
0 - 20][
0 - 50][
40-56][
40-60]
| Ident. | Authors (with country if any) | Title |
|---|
| 001474 (2012) |
Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Nègre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarié [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France] | A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease |
| 001574 (2011) |
Philippe Huot [Canada] ; Susan H. Fox ; Jonathan M. Brotchie | The serotonergic system in Parkinson's disease. |
| 001608 (2011) |
Ruediger Hilker [Allemagne] ; Jonathan M. Brotchie [Canada] ; Joab Chapman [Israël] | Pros and cons of a prion-like pathogenesis in Parkinson's disease |
| 001610 (2011) |
James B. Koprich ; Tom H. Johnston ; Philippe Huot ; M. Gabriela Reyes ; Maria Espinosa ; Jonathan M. Brotchie | Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein |
| 001723 (2011) |
Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. Brotchie | Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? |
| 001743 (2011) |
Philippe Huot [Canada] ; Jonathan M. Brotchie | 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms. |
| 001778 (2011) |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001986 (2010) |
Susan H. Fox [Canada] ; Jonathan M. Brotchie | The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. |
| 001996 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox ; Matthew J. Mcildowie ; Matthew J. Piggott ; Jonathan M. Brotchie | Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001A47 (2010) |
James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; M Gabriela Reyes [Canada] ; Xuan Sun [Canada] ; Jonathan M. Brotchie [Canada] | Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease |
| 001B24 (2010) |
Michael N. Gandy [Australie] ; Matthew Mcildowie [Australie] ; Katie Lewis [Australie] ; Agata M. Wasik [Royaume-Uni] ; Danielle Salomonczyk [Canada] ; Keith Wagg [Australie] ; Zak A. Millar [Australie] ; David Tindiglia [Australie] ; Philippe Huot [Canada] ; Tom Johnston [Canada] ; Sherri Thiele [Canada] ; Blake Nguyen [Australie] ; Nicholas M. Barnes [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Mathew T. Martin-Iverson [Australie] ; Joanne Nash [Canada] ; John Gordon [Royaume-Uni] ; Matthew J. Piggott [Australie] | Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity |
| 001B51 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001C09 (2010) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
| 001C36 (2010) |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
| 001C77 (2010) |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 001C89 (2010) |
Susan H. Fox [Canada] ; Naomi Visanji [Canada] ; Gaby Reyes [Canada] ; Philippe Huot [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom Johnston [Canada] ; Jonathan M. Brotchie [Canada] | Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease |
| 001D05 (2010) |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations |
| 001F59 (2009) |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's disease: On movement, mood, and madness |
| 002158 (2008) |
Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. Brotchie | Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. |
| 002166 (2008) |
Susan H. Fox [Canada] ; Jonathan M. Brotchie ; Anthony E. Lang | Non-dopaminergic treatments in development for Parkinson's disease. |
| 002281 (2008) |
Joohyung Lee [Canada, Australie] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi Visanji [Canada] ; Jonathan M. Brotchie [Canada] | Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i -k "Jonathan M. Brotchie"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Author.i \
-Sk "Jonathan M. Brotchie" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= indexItem
|index= Author.i
|clé= Jonathan M. Brotchie
}}
| This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022 |  |
